Nurix Therapeutics Inc (NRIX) financials
Nurix Therapeutics revenue and earnings by year
Nurix Therapeutics's revenue was $84.0 million in the fiscal year to November 30, 2025, up 54.0% from the year before. Net income was -$264 million, -314.9% of revenue. Since the fiscal year to November 30, 2019, revenue has grown 18.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | Nov 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 84 | 55 | 77 | 39 | 30 | 18 | 31 |
| Revenue growth | 54.0% | -29.1% | 99.3% | 29.8% | 66.9% | -42.7% | — |
| Operating income | -286 | -213 | -155 | -184 | -118 | -65 | -22 |
| Operating margin | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | -364.7% | -71.5% |
| Net income | -264 | -194 | -144 | -180 | -117 | -43 | -22 |
| Net margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% | -69.7% |
| Diluted EPS | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | — | — |
| Free cash flow | -263 | -182 | -90 | -172 | -90 | -5 | -1 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open NRIX in Markets.
How Nurix Therapeutics makes money
Revenue by segment in the quarter to August 31, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| License Revenue | $653M | 97.0% |
| Collaboration Revenue | $19.9M | 3.0% |
See also: NRIX valuation and P/E history · NRIX returns
No forecast, no recommendation. This page describes Nurix Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.